Elite Pharmaceuticals shares close at $0.24 ahead of management call on results
Key Facts
Elite Pharmaceuticals shares closed at $0.24 on November 11, 2026, according to EL7 data, ahead of a call the company said would address fiscal 2027 second-quarter results and a commercial update. The company set November 12 as the date for releasing results, followed by the call on November 13 at 11:30 a.m. Eastern Time, according to its disclosure. These dates put second-quarter results at the forefront of investor attention on the company. The company had said management would discuss the results and commercial update during the call. The available information here does not include the second-quarter results themselves, so the closing price and the latest documented financial comparisons remain the figures cited in this coverage.
In fiscal 2027’s first quarter, the company reported revenue of $32.4 million for the three months ended June 30, 2026, compared with $40.2 million in the same period a year earlier, according to its filing with the U.S. Securities and Exchange Commission. Gross margin was 42% for the quarter, versus 68% in the comparable period. The company attributed the decline in margin to lower average net prices resulting from increased market competition. Operating income was $7.5 million, compared with $21.7 million for the three months ended June 30, 2025. These figures provide context on revenue and profitability ahead of the second-quarter results, but relate to the June period and do not represent the results the company scheduled for release in November.
Earlier in the fiscal year, the company announced on August 4, 2026, the launch of its generic version of Requip XL, an extended-release ropinirole drug, in 2, 4, 6, 8 and 12 mg strengths. The company’s report said the product is marketed under the Elite Laboratories brand. The launch forms part of the commercial context that management said it would address on the November call. The earlier disclosure noted that competition and lower average net prices had affected gross margin in the June quarter. Investors are awaiting details on the results and commercial update from management at the scheduled call.